NCT00033228View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage IV Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

March 31, 2003

Study Completion Date

April 30, 2003

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

MKC1106-MT

Cancer Vaccine, Immunotherapy, 500 ug

BIOLOGICAL

MKC1106-MT

Cancer Vaccine, Immunotherapy, 1000 ug

BIOLOGICAL

MKC1106-MT

Cancer Vaccine, Immunotherapy, 1500 ug

Trial Locations (5)

55905

Mayo Clinic Cancer Center, Rochester

85724

Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson

90089

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

02118

Cancer Research Center at Boston Medical Center, Boston

97213-2967

Earle A. Chiles Research Institute at Providence Portland Medical Center, Portland

Sponsors
All Listed Sponsors
lead

Mannkind Corporation

INDUSTRY